drugset / Trial / NCT00253188
A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety and effectiveness of two doses of galantamine (a drug for treating dementia) versus placebo in the treatment of patients with Alzheimer's disease.
Timeline
- Start
- 1997-02
- Primary completion
- —
- Completion
- 1998-12
Publications
- Results Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ. 2000 Dec 9;321(7274):1445-9. doi: 10.1136/bmj.321.7274.1445.
- Results Pirttila T, Wilcock G, Truyen L, Damaraju CV. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. Eur J Neurol. 2004 Nov;11(11):734-41. doi: 10.1111/j.1468-1331.2004.00885.x.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Galantamine | Small molecule | 12 mg | Oral |
| Subject | Galantamine | Small molecule | 16 mg | Oral |